A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection

Running title: Bivalent vaccine for respiratory infectious disease

Hiroaki Katsura1,*, Zhenyu Piao2,*, Kiyoko Iwatsuki-Horimoto1, Yukihiro Akeda2, Shinji Watanabe3,4, Taisuke Horimoto5, Kazunori Oishi2,6,†, Yoshihiro Kawaoka1,3,7,8,‡

1Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Tokyo, Japan
2Laboratory of Clinical Research on Infectious Diseases, International Research Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
3ERATO Infection-Induced Host Responses Project, Japan Science and Technology agency, Saitama, Japan
4Laboratory of Veterinary Microbiology, Department of Veterinary Sciences, University of Miyazaki, Miyazaki, Japan
5Department of Veterinary Microbiology, Graduate School of Agriculture and Life Science, University of Tokyo, Tokyo, Japan.
6Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Tokyo, Japan
7Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 575 Science Drive, Madison, WI, USA
8Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan

*These authors contributed equally to this work.

†,‡ Corresponding authors and mailing addresses:

†Kazunori Oishi
Abstract: 220 words (<250 words)
Text: 3499 words
Number of figures: 5
Number of tables: 1
Abstract

Streptococcus pneumoniae (S. pneumoniae) is a major causative pathogen in community-acquired pneumonia; together with influenza virus, it represents an important public health burden. Although vaccination is the most effective prophylaxis against these infectious agents, no single vaccine simultaneously provides protective immunity against both S. pneumoniae and influenza virus. Previously, we demonstrated that several replication-incompetent influenza viruses efficiently elicit IgG in serum and IgA in the upper and lower respiratory tracts. Here, we generated a replication-incompetent hemagglutinin-knockout (HA-KO) influenza virus possessing the sequence for the antigenic region of pneumococcal surface protein A (PspA). Although this virus (HA-KO/PspA virus) could replicate only in an HA-expressing cell line, it infected wild-type cells and expressed both viral proteins and PspA. PspA- and influenza virus-specific antibodies were detected in nasal wash, bronchoalveolar lavage, and serum from mice intranasally inoculated with HA-KO/PspA virus, and mice inoculated with HA-KO/PspA virus were completely protected from lethal challenge with either S. pneumoniae or influenza virus. Further, bacterial colonization of the nasopharynx was prevented in mice immunized with HA-KO/PspA virus. These results indicate that HA-KO/PspA virus is a promising bivalent vaccine candidate that simultaneously confers protective immunity against both S. pneumoniae and influenza virus. We believe that this strategy offers a platform for the development of bivalent vaccines, based on replication-incompetent influenza virus, against pathogens that cause respiratory infectious diseases.
Importance (<150 words)

Streptococcus pneumoniae and influenza viruses cause contagious diseases, but no single vaccine can simultaneously provide protective immunity against both pathogens. Here, we used reverse genetics to generate a replication-incompetent influenza virus carrying the sequence for the antigenic region of pneumococcal surface protein A and demonstrated that mice immunized with this virus were completely protected from lethal doses of infection with either influenza virus or Streptococcus pneumoniae. We believe that this strategy, which is based on a replication-incompetent influenza virus possessing the antigenic region of other respiratory pathogens, offers a platform for the development of bivalent vaccines.

(97 words)

Keyword

bivalent vaccine, replication-incompetent influenza virus, mucosal immunity
**Introduction**

*Streptococcus pneumoniae (S. pneumoniae)* is a Gram-positive aerobic bacterial species for which there are more than 90 serotypes based on the chemical and serological features of its capsular polysaccharides. *S. pneumoniae* is a common cause of community-acquired pneumonia, and its colonization of the nasopharynx always precedes infections such as otitis media, sinusitis, pneumonia, and meningitis (1-4). Pneumococcal carriage is an important source of the horizontal spread of this pathogen within the community, because pneumococcal diseases do not occur without preceding nasopharyngeal colonization (1).

The pneumococcal conjugate vaccine can induce serotype-specific antibodies in children, and is thought to reduce the nasopharyngeal carriage of vaccine-type pneumococci in children (5, 6). The introduction in 2000 of the seven-valent pneumococcal conjugate vaccine for children in the United States younger than 2 years, as well as children aged 2–4 years in a high-risk category, was effective, dramatically reducing the incidence of invasive pneumococcal disease (7, 8). However, although several studies have demonstrated the protective efficacy of pneumococcal conjugate vaccines, they are ineffective against invasive pneumococcal disease caused by serotypes that are not included in the vaccine. Therefore efforts are ongoing to develop a vaccine that is effective regardless of serotype. Several proteins that are expressed on the surface of the bacteria, such as choline-binding protein A and pneumococcal surface adhesin A are considered attractive antigens for a new vaccine (1, 2, 9, 10). Among them, pneumococcal surface protein A (PspA) is thought to be particularly promising. PspA is found in all clinical *S. pneumoniae* isolates (11). Some studies have demonstrated that antibodies against PspA neutralize the anticomplement effect of PspA, which results in clearance of the bacteria by depositing complement C3 on the bacterial surface (12, 13). Moreover, anti-PspA antibodies have also been shown to prevent infection from strains with different serotypes (14). We previously reported that mice immunized with recombinant PspA protein in combination with polyinosinic-polycytidylic acid (poly(I:C)), a Toll-like receptor (TLR) agonist, as
an adjuvant, were completely protected against secondary pneumococcal pneumonia after influenza virus infection (15). Moreover, in human trials, intramuscular immunization with the recombinant PspA protein induced cross-reactive antibodies to heterologous PspA (14).

Influenza virus also causes serious respiratory infections, and inactivated and live-attenuated influenza vaccines are approved for prophylaxis against influenza. Although inactivated vaccines are highly safe and induce IgG in sera, they cannot elicit secretory IgA at the mucosal surface of the respiratory tract where influenza virus replicates. Intranasal administration of live-attenuated vaccines, which carry mutations that lead to temperature sensitivity and viral attenuation, induces not only IgG in sera, but also IgA at the mucosal surface. However, live-attenuated vaccines are not recommended for children under the age of 2, adults aged 50 or over, immunocompromised patients, or pregnant women (16-18). To overcome these limitations, efforts are ongoing to develop an ideal influenza vaccine that is highly safe and induces secretory IgA at the mucosal surface of the respiratory tract.

Recently, we established a replication-incompetent influenza virus that possesses a hemagglutinin (HA) that is not cleaved into HA 1 and HA 2 by proteases (uncleavable HA virus) (19). We demonstrated that this uncleavable HA virus could infect and express viral protein in wild-type cells, but does not produce infectious progeny viruses in these cells; however, it could induce virus-specific humoral and cellular immunity in the respiratory tracts of immunized mice. Given that this replication-incompetent virus can be propagated in an HA-expressing cell line, this system could be used to generate bivalent vaccines in which the antigen gene of another respiratory pathogen is introduced into the HA gene. To assess this possibility, here we generated an HA-knock-out (KO) PspA virus as a bivalent vaccine candidate, possessing the PspA antigen gene instead of the HA gene, and examined its immunogenicity and vaccine efficacy against both influenza virus and S. pneumoniae in mice.
Material and Methods

Cells. Madin-Darby canine kidney (MDCK) cells were maintained in minimum essential medium (MEM) containing 5% of newborn calf serum (NCS). Human embryonic kidney 293T (HEK293T) cells were maintained in Dulbecco’s modified Eagle medium supplemented with 10% fetal calf serum. MDCK cells expressing HA (HA-MDCK) were established by co-transfection with plasmids for the expression of HA derived from A/Puerto Rico/8/34 (PR8) and puromycin N-acetyltransferase as previously described (19). HA-MDCK cells were cultured in MEM containing 5% NCS and 5 μg/ml puromycin dihydrochloride (Nacalai Tesque).

Preparation of virus and bacteria. PR8 was generated by using reverse genetics (20) and propagated in MDCK cells at 37°C. Forty-eight hours after infection, the supernatants were harvested and stored at -80°C until use. S. pneumoniae WU2 strain with serotype 3 and EF3030 strain with serotype 19F, which is virulent and relatively avirulent in mice, (21, 22) were grown in Todd-Hewitt Broth (Becton, Dickinson and Company) supplemented with 0.5% yeast extract (THY) to mid-log phase and washed twice with Dulbecco’s phosphate-buffered saline (PBS) without CaCl$_2$ and MgCl$_2$ (Sigma-Aldrich). The bacteria were then suspended in THY containing 10% glycerol, aliquoted, and stored at -80°C until use.

Plasmid construction. For viral RNA (vRNA) expression, plasmids containing the cDNAs of PR8 genes between the human RNA polymerase I promoter and the mouse RNA polymerase I terminator (referred to as PolI plasmid) were generated. To generate plasmids that express the PspA antigenic region or green fluorescence protein (GFP) from the HA segment, we utilized the packaging signal of the HA segment of influenza virus (23). Plasmids (pPolI-HA(9)PspA(80) and pPolI-HA(9)GFP(80)) were constructed to replace the PolI plasmid that encoded the HA segment of PR8. These plasmids contained the 3’ HA non-coding region, 9 nucleotides that correspond to the
HA-coding sequence at the 3’ end of the vRNA followed by the PspA antigenic region of the Rx1 strain (serotype 2) (amino acid positions 32–333) or the GFP-coding sequence, 80 nucleotides that correspond to the HA-coding sequence at the 5’ end of the vRNA, and lastly the 5’ HA non-coding region. The sequences were determined to ensure that no unwanted mutations were introduced. Primer sequences are available upon request.

**Plasmid-driven reverse genetics.** To generate the viruses that possess the HA segment encoding the PspA antigenic region (HA-KO/PspA virus) or GFP (HA-KO/GFP virus), we used plasmid-driven reverse genetics as described previously (20). Briefly, pPolI-HA(9)PspA(80) or pPolI-HA(9)GFP(80) and the remaining 7 PolI plasmids were cotransfected into HEK293T cells together with eukaryotic protein expression plasmids for PB2, PB1, PA, NP, and wild-type HA derived from PR8 by using the TransIT-293 transfection reagent (Mirus). Forty-eight hours after transfection, the supernatants containing the HA-KO/PspA virus or the HA-KO/GFP virus were harvested and propagated once in HA-MDCK cells at 37°C for 48 h in MEM containing L-(tosylamido-2-phenyl) ethyl chloromethyl ketone-treated trypsin (0.8 μg/ml) and 0.3% bovine serum albumin (BSA) (Sigma Aldrich). Cell debris was removed by centrifugation at 2,100 x g for 20 min at 4°C, and the supernatants were stored at -80°C until use. The virus titers were determined by counting cells expressing PspA or GFP by immunostaining or fluorescence observation, respectively, after a plaque assay using HA-MDCK cells.

**Immunofluorescence assay.** MDCK and HA-MDCK cells were infected with PR8 or HA-KO/PspA virus at an MOI of 0.0001. Thirty-six hours after infection, the cells were washed twice with PBS and fixed with 4% paraformaldehyde for 10 minutes. After permeabilization with PBS containing 0.2% Triton X-100, the cells were incubated with a mouse anti-PspA antiserum and with rabbit antiserum against influenza virus (A/WSN/33). Goat anti-mouse IgG Alexa 488 and anti-rabbit IgG Alexa 594 (molecular probes) served as secondary antibodies. Cells were observed by
Immunization and protection test. Seven-week-old female C57BL/6 mice (Japan SLC) were intranasally inoculated with 50 µl of 10^5 plaque-forming units (PFU) of HA-KO/PspA virus twice, with a 2-week interval between the inoculations. As control groups, age-matched female C57BL/6 mice were intranasally inoculated with 50 µl of 10^5 PFU of HA-KO/GFP virus or medium on the same schedule. Two weeks after the final vaccination, six mice per group were euthanized to obtain sera, bronchoalveolar lavage fluid (BALF), and nasal washes. Also two weeks after the final vaccination, mice were challenged with 100 times the 50% mouse lethal dose (MLD50) of PR8 virus. Eight mice per group were monitored for survival and body weight changes for 14 days after PR8 challenge. Lungs and nasal turbinates from three mice per group were collected on days 3 and 6 after challenge to determine virus titers. Virus titers were determined on MDCK cells. In addition, two weeks after the final vaccination, mice were intranasally challenged with 3 MLD50 of S. pneumoniae WU2 strain. Ten mice per group were monitored for survival for 14 days after challenge. Similarly, two weeks after the final vaccination, mice were intranasally challenged with 1.0 x 10^2 colony-forming units (cfu) of S. pneumoniae EF3030 strain. Nasal washes from ten mice per group were collected on day 5 after challenge to determine the bacterial clearance from the nasopharynx. The quantitative bacterial culture of the nasal washes was performed.

Detection of pathogen-specific antibodies. Pathogens-specific antibodies in nasal washes, BALF, and serum were detected by means of an enzyme-linked immunosorbent assay (ELISA) (24). To detect virus-specific antibodies, we used 2-fold serially diluted serum, BALF, and nasal washes. In this assay, 96-well ELISA plate wells were coated with approximately 200 hemagglutination units (in 50 µl) of purified PR8 virus treated with disruption buffer (0.5M Tris-HCl [pH 8.0], 0.6M KCl, and 0.5% Triton X-100). After the diluted samples were incubated on the virus-coated plates for 1 h at room temperature, goat anti-mouse IgA or IgG antibody conjugated to horseradish peroxidase
(Kirkegaard & Perry Laboratory Inc.) was added to detect bound antibody. The optical density (OD) was measured at 405 nm with a microplate reader. End-point titers are expressed as the reciprocal \( \log_2 \) of the last dilution whose OD value was more than the cut-off value. The cut-off value was determined by adding threefold standard deviations (SD) to the mean (i.e., mean + 3 SD) of the OD values of samples from naïve mice. PspA-specific antibody titers in nasal washes, BALF, and serum were determined by use of an ELISA as previously described (15). Microtiter plates were coated overnight at 4 °C with 100 µl of 1 µg/ml of PspA. The plates were then washed with PBS with 0.05% Tween 20 (PBS-T). Serially diluted nasal washes, BALF, and serum (50 µl) were added to the plates, and the plates were then incubated for 30 min at 37 °C. The plates were washed three times with PBS-T and incubated with alkaline phosphatase-conjugated goat anti-mouse IgG, IgG1, IgG2a or IgA (Zymed) for 30 min at 37 °C. After this incubation, the plates were washed three times with PBS-T, and then 4-nitrophenyl phosphate disodium salt hexahydrate (Sigma–Aldrich) diluted with substrate buffer (1M diethanolamine, 0.5 mM MgCl\(_2\)) was added; the plates were then incubated for 30 min at room temperature in the dark. The OD at 405 nm was then measured with a microplate reader (Bio-Rad Laboratories). The end-point titers were expressed as the reciprocal \( \log_2 \) of the last dilution giving 0.1 OD unit of OD\(_{405}\) above the OD\(_{405}\) of negative control samples obtained from non-immunized mice.
Results

PspA and GFP expression in infected cells. To examine whether PspA was expressed in HA-KO/PspA virus-infected cells, we infected MDCK and HA-MDCK cells with HA-KO/PspA virus and attempted to detect PspA in virus-infected cells by use of an immunofluorescence assay. PR8 served as a control. PspA expression was detected in both cell types infected with HA-KO/PspA virus, but not in cells infected with PR8 (Fig. 1). Although HA-KO/PspA virus could efficiently spread and express its viral proteins and PspA in HA-MDCK cells, the infection of HA-KO/PspA virus did not spread in MDCK cells (Fig. 1). In both cell types infected with HA-KO/PspA virus, we found some cells that expressed the viral proteins, but not PspA (Fig. 1, white arrows). This may be because the HA segment encoding the PspA antigenic region was not incorporated into the virus particles that infected those cells. This is not surprising because not all virions contain authentic viral RNA segments (25). Taken together, these results indicate that HA-KO/PspA virus is replication-incompetent, but can express not only viral proteins but also PspA in virus-infected cells. We obtained similar results with HA-KO/GFP virus (data not shown).

Induction of antibodies against PspA and influenza virus by HA-KO/PspA virus. To assess the ability of HA-KO/PspA virus to induce antibodies against both PspA and PR8, mice were intranasally inoculated twice with $10^5$ PFU of HA-KO/PspA virus. Mice inoculated with HA-KO/GFP virus or medium served as controls. Two weeks after the final vaccination, nasal washes, BALF, and serum were collected and subjected to ELISA to measure antigen-specific IgG and IgA in these samples. The induction of IgG against PR8 was detected in serum samples from mice inoculated with HA-KO/PspA or HA-KO/GFP virus (Fig. 2A). Moreover, both IgG and IgA against PR8 were detected in nasal washes and BALF from these mice, although IgA in the nasal washes of mice inoculated with HA-KO/PspA virus was not significantly induced compared with one in the nasal washes of mice inoculated with medium (Figs. 2B and C). These results indicate that
the HA-KO/PspA and HA-KO/GFP viruses elicited both virus-specific mucosal and systemic immunity. On the other hand, for the antibody response to PspA, both IgG and IgA titers in the BALF and IgG titers in the serum and nasal washes significantly increased only in mice inoculated with HA-KO/PspA virus (Figs. 3A, B, and C). Likewise, PspA-specific IgG1 and IgG2a titers were also elevated in the serum of these mice (Figs. 3D). While both isotypes inhibit the anticomplement effect of PspA, the complement-fixing ability of IgG2a is superior to that of other isotypes (26). Therefore, the increase in IgG2a titer in mice inoculated with HA-KO/PspA represents a significant response in terms of the efficient clearance of *S. pneumoniae* via opsonophagocytic killing. A PspA-specific antibody response was not observed in samples from mice inoculated with HA-KO/GFP virus or medium. These results indicate that HA-KO/PspA virus can induce a significant antibody response against both influenza virus and PspA at the mucosal surface of the respiratory tract and in blood.

**Protective efficacy of HA-KO/PspA virus against lethal doses of *S. pneumoniae* and influenza virus.** To evaluate the protective efficacy of HA-KO/PspA virus against *S. pneumoniae* and influenza virus, we performed a challenge experiment. Mice were intranasally inoculated with medium, HA-KO/GFP, or HA-KO/PspA virus on the same schedule as the aforementioned experiment. Two weeks after the final vaccination, these mice were infected with lethal doses of either PR8 or *S. pneumoniae* serotype 3 strain WU2. Their body weight changes and survival were monitored during the observation period.

In the case of influenza virus infection, the body weights of mice inoculated with medium rapidly decreased and all mice died by day 5 after infection (Fig. 4). On the other hand, mice inoculated with either HA-KO/PspA or HA-KO/GFP virus showed no reduction in body weight and all of these mice survived during the observation period (Fig. 4). We also determined virus titers in the lungs and nasal turbinates of each group of mice after challenge (Table 1). Although virus was recovered from the lungs of 2 out of 3 mice inoculated with HA-KO/PspA virus on day 3 after
challenge, virus titers were appreciably lower than those in the lungs of mice inoculated with medium. Further, except for the lungs of these mice, virus in the nasal turbinates and lungs of mice inoculated with HA-KO/PspA or HA-KO/GFP virus was undetectable on days 3 and 6 after challenge. These results indicate that the HA-KO/PspA and HA-KO/GFP viruses confer protective immunity to mice against a lethal dose of influenza virus.

With regard to the S. pneumoniae infection, all mice mock-immunized with medium died when challenged with S. pneumoniae WU2 strain of serotype 3. Moreover, in contrast to the PR8 infection, all mice immunized with HA-KO/GFP virus also died. However, all mice immunized with HA-KO/PspA virus survived (Fig. 5A). To determine the effect of the vaccine on the level of bacterial colonization of the nasopharynx, we challenged immunized mice with S. pneumoniae serotype 19F strain EF3030; we did not use S. pneumoniae WU2 for this experiment because it causes bacteremia, which would make it problematic to differentiate true bacterial colonization from bacteria derived from blood. Although the bacterial densities of the nasopharynx of mice inoculated with HA-KO/GFP virus were comparable to those of the nasopharynx of mice inoculated with medium, the bacterial densities of the nasopharynx of mice inoculated with HA-KO/PspA virus were significantly lower than those of the nasopharynx of mice inoculated with medium or HA-KO/GFP virus (Fig. 5B). These results indicate that HA-KO/PspA virus confers immunity against S. pneumoniae of a heterologous serotype because the PspA gene in HA-KO/PspA virus was derived from serotype 2 (strain Rx1) which differs from the serotype of the challenge bacterium (i.e., serotypes 3 and 19F).

Overall, these results demonstrate that HA-KO/PspA virus provides protective immunity to mice against lethal infection with influenza virus and S. pneumoniae, suggesting that HA-KO virus can be used as a platform for a bivalent vaccine against respiratory infectious diseases.
Discussion

Secondary bacterial infections after influenza virus infections complicate disease severity and increase mortality and morbidity. Indeed, most victims of the 1918–19 influenza virus pandemic likely died from secondary bacterial pneumonia (27). In addition, autopsy samples from those who succumbed to infection with the 2009 pandemic H1N1 influenza virus exhibited signs of secondary bacterial infections, and the severity of the infections caused by this influenza virus was correlated with \textit{S. pneumoniae} coinfection (28, 29). Damage to mucosal epithelial cells, exposure of receptors that facilitate bacterial adherence, and dysfunction of immune effectors by influenza virus infection are prominent features that allow bacteria access to the lower respiratory tract (4). It was, therefore, once thought that pneumococcal disease could be prevented by administering influenza vaccine alone because if the influenza virus infection was prevented, the above-described features that contribute to bacterial invasion would be minimized (30, 31). However, such complete protection from bacterial infections through influenza vaccination alone is unlikely because of the lack of specific immunity against the bacteria. Therefore, the induction of antibodies against \textit{S. pneumoniae} via vaccination is important to prevent such bacterial infections. Here, we generated a replication-incompetent HA-KO virus that encodes the PspA antigenic region in the coding region of its HA segment (HA-KO/PspA virus). This virus induced not only influenza virus- but also PspA-specific antibodies on the respiratory mucosa and in the sera of mice. We also demonstrated that mice inoculated with HA-KO/PspA virus were completely protected from lethal challenge with both \textit{S. pneumoniae} and influenza virus. In addition, we also demonstrated that nasal immunization with HA-KO/PspA virus significantly decreased the levels of bacterial colonization in the nasopharynx of mice. Therefore, our findings suggest that nasal immunization with HA-KO/PspA virus can prevent pneumococcal colonization and protect against lethal infections due to both \textit{S. pneumoniae} and influenza virus. Therefore, The HA-KO/PspA virus is a promising bivalent vaccine against these important respiratory pathogens.
It has been previously demonstrated that intranasal administration of the PspA protein alone does not elicit an adequate antibody response and that administration of PspA with adjuvants, such as different types of TLR ligands, can confer sufficient immunity against *S. pneumoniae* in mice (32). Remarkably, however, we demonstrated that HA-KO/PspA virus induced efficient immunity against *S. pneumoniae* infection without any mucosal adjuvants. The possible mechanisms are as follows: first, infection with HA-KO/PspA virus triggers the innate immune response via recognition of vRNAs by pattern-recognition receptors, such as TLR7 (33) and Retinoic acid-inducible gene-I (RIG-I) (34, 35), in the infected cells since these vRNAs are amplified in HA-KO/PspA virus-infected cells even though infectious progeny virus cannot be generated; second, PspA is expressed in virus-infected cells as shown in Fig. 1; and third, antigen-presenting cells (APCs) phagocytose the infected cells that contain the ligands for the TLRs (vRNAs) and the antigens (PspA besides viral proteins), and the major histocompatibility complex classes I and II efficiently present these antigens on the cell surface of the APCs (36, 37). As such, it is possible for PspA-specific antibodies to be induced by HA-KO/PspA virus in the absence of any exogenous mucosal adjuvants.

In conclusion, the replication-incompetent influenza virus-based approach presented here could be used as a platform to develop bivalent vaccine candidates against various pathogens that cause respiratory infectious diseases.
Acknowledgements

We thank Takeo Gorai, Ryuta Uraki, and Eiryo Kawakami for helpful discussion, and Susan Watson for editing the manuscript. We are also grateful to David E. Briles from the University of Alabama at Birmingham for providing the pneumococcal strains. This work was supported by the Advanced Research for Medical Products Mining Programme of the National Institute of Biomedical Innovation (NIBIO), by grants-in-aid from the Ministry of Health, Labour and Welfare, Japan, by ERATO (Japan Science and Technology Agency), by the Strategic Basic Research Programs of the Japan Science and Technology Agency, and by National Institute of Allergy and Infectious Diseases Public Health Service research grants. H.K is supported by a Grant-in-Aid from the Japan Society for the Promotion of Science.
References


Figure 1. Expression of the PspA antigenic region and viral proteins in cells infected with PR8 or HA-KO/PspA virus. MDCK and HA-MDCK cells were infected with the respective virus at an MOI of 0.0001, and an immunofluorescence assay was performed 36 h post-infection. PspA (green) and viral proteins (red) were detected by anti-PspA and anti-WSN antibodies, respectively. White arrows indicate cells that express the viral proteins but not the PspA protein.
Figure 2. Induction of influenza virus-specific IgG and IgA in serum (A), nasal washes (B), and BALF (C). Mice were intranasally inoculated with medium, HA-KO/GFP virus, or HA-KO/PspA virus with a two-week interval between the inoculations. Samples from six mice from each group were collected two weeks after the final vaccination. Virus-specific antibodies were detected by using an ELISA. Results are expressed as the means of the reciprocal titer log₂ (± standard deviations (SD)). Statistically significant differences between groups were determined by using the Dunnet method. The asterisk indicates a significant difference from samples taken from mice inoculated with medium (*, P<0.05).
Figure 3. Induction of PspA-specific IgG and IgA levels in nasal washes (A), and BALF (B), and IgG levels in serum (C), as well as IgG1 and IgG2a levels in serum (D). Mice were intranasally inoculated with medium, HA-KO/GFP virus, or HA-KO/PspA virus with a two-week interval between the inoculations. Samples from six mice from each group were collected two weeks after the final vaccination. PspA-specific antibodies were detected by use of an ELISA. Results are expressed as the means of the reciprocal titer log₂ (± SD). Statistically significant differences between groups were determined by using the Dunnet method. The asterisk indicates a significant difference from samples taken from mice inoculated with medium (*, P<0.05).
Figure 4. Body weight changes and survival curves for mice challenged with lethal doses of PR8. Eight mice per group were intranasally infected with 100 MLD$_{50}$ of PR8 two weeks after their final vaccination. Body weights were measured (A) and survival rate was monitored (B) for 14 days after infection. Open triangles, mice inoculated with medium; open squares, mice inoculated with HA-KO/GFP virus; closed circles, mice inoculated with HA-KO/PspA virus.
Figure 5. Survival curves for mice challenged with lethal doses of *S. pneumoniae* WU2 strain, and bacterial densities in the nasopharynx 5 days after challenge with *S. pneumoniae* EF3030 strain. (A) Ten mice per group were intranasally infected with 3 MLD$_{50}$ of WU2 strain two weeks after their final vaccination. The survival rate was monitored for 14 days after infection. Open triangles, mice inoculated with medium; open squares, mice inoculated with HA-KO/GFP virus; closed circles, mice inoculated with HA-KO/PspA virus. (B) Mice were intranasally infected with $1 \times 10^2$ cfu/mouse of EF3030 strain two weeks after their final vaccination. Five days after challenge with EF3030 strain, nasal washes were collected, and a quantitative bacterial culture of nasal washes was performed. Values represent the log$_{10}$ cfu/ml (mean ± SD) for ten mice per group. Closed circles, mice inoculated with medium; closed squares, mice inoculated with HA-KO/GFP virus; closed triangles, mice inoculated with HA-KO/PspA virus. Statistically significant differences between groups were determined by using the Kaplan-Meier log-rank test for the survival analysis or the Mann-Whitney test for the bacterial clearance analysis. The asterisk indicates a significant difference (*, $P<0.05$).
Table 1. Protection against challenge with a lethal dose of PR8 in mice inoculated with HA-KO/GFP or HA-KO/PspA virus.

<table>
<thead>
<tr>
<th>Challenge dose</th>
<th>inoculum</th>
<th>days post-infection</th>
<th>organ</th>
<th>Virus titer (mean ± SD log10[PFU/g])</th>
</tr>
</thead>
<tbody>
<tr>
<td>100MLD&lt;sub&gt;50&lt;/sub&gt; Medium</td>
<td>3dpi</td>
<td>NT&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Lung</td>
<td>6.3 ± 0.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7.9 ± 0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6dpi</td>
<td>NT&lt;sup&gt;b&lt;/sup&gt;</td>
<td>NA&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lung</td>
<td>NA</td>
</tr>
<tr>
<td>HA-KO GFP</td>
<td>3dpi</td>
<td>NT&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Lung</td>
<td>ND&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6dpi</td>
<td>NT&lt;sup&gt;b&lt;/sup&gt;</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lung</td>
<td>ND</td>
</tr>
<tr>
<td>HA-KO PspA</td>
<td>3dpi</td>
<td>NT&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Lung</td>
<td>2.9, 4.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6dpi</td>
<td>NT&lt;sup&gt;b&lt;/sup&gt;</td>
<td>ND</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lung</td>
<td>ND</td>
</tr>
</tbody>
</table>

<sup>a</sup> Six mice from each group were intranasally infected with 100 MLD<sub>50</sub> of PR8 (50 μl per mouse) two weeks after the final vaccination. Three mice per group were sacrificed on days 3 and 6 post-infection, and lungs and nasal turbinate were collected to determine virus titers. Results are expressed as the mean titer (log<sub>10</sub> PFU/g) ± standard deviations (SD). When virus was not recovered from all three mice, individual titers are given.

<sup>b</sup> NT: Nasal turbinate

<sup>c</sup> NA: Not applicable because the mice died

<sup>d</sup> ND: Not detected (detection limit, 10 PFU/lung or 5 PFU/NT)